Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed is supported by a differentiated AI-enabled aprevo platform that customizes spinal implants to patient anatomy, with strong clinical evidence showing a 4.3% revision rate versus 16.6% for stock implants and favorable payer reimbursement that can add meaningful facility economics. Its growth profile is reinforced by rising surgeon adoption, with active surgeon onboarding climbing into the low-30s in 4Q25 and 1Q26, while revenue guidance of about $74 million to $78 million in FY26 implies 46.5% to 54.4% year-over-year growth and gross margin in the mid-to-high 70s. With cervical traction, new launches on track for 4Q26, and a capital-light model that may reach profitability on a lower revenue base than traditional spine peers, the company appears well positioned for sustained expansion and operating leverage.

Carlsmed is exposed to a difficult competitive backdrop in which the top five public incumbents hold about 75% of the global spine market, and larger rivals like Globus Medical are introducing personalized platforms that could pressure adoption of Aprevo and limit share gains. Its downside is amplified by dependence on rapid surgeon uptake, favorable reimbursement that may not last, and execution risk around expansion into cervical spine, while the company remained unprofitable and ended 1Q26 with $97 million in cash and investments plus access to an additional $35 million credit facility. With 2026-2028 consensus EBITDA still negative at ($33M), ($27M), and ($12M), any revenue disappointment or slower path to breakeven could trigger multiple contraction and weaken the stock.